convalescent plasma treatment – Page 2 – Communicable Diseases Research

Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression

COVID-19에 대한 회복기 혈장: 메타 분석, 시험 순차 분석 및 메타 회귀

Meta-Analysis

Published on 2021-12-012022-09-11
Journal: British journal of anaesthesia [Category] 임상,

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

COVID-19에서의 회복기 혈장 치료와 사망률 사이의 연관성 : 무작위 임상 시험의 협력 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-11-202022-09-01
Journal: BMC Infectious Diseases [Category] MERS, SARS, 비임상, 임상, 진단,

[키워드] all-cause mortality benefit breath chance clinical clinical trial registry clinical trials control patients convalescent plasma convalescent plasma treatment COVID-19 COVID-19 patients database did not reduce died email enrolled Evidence heterogeneity hospitalized patient intensive care investigated investigator investigators Meta-analysis Mortality mortality data ongoing trial open Open Science Framework Patient Patient care patients patients with COVID-19 Placebo plasma provided random effect randomized clinical trial randomized clinical trials randomized trials RECOVERY trial Registered registry Result risk risk ratio SARS-CoV-2 searched supplementary material systematic review treat Treatment Trial trials weight WHO WHO International Clinical Trials Registry Platform
[DOI] 10.1186/s12879-021-06829-7 PMC 바로가기 [Article Type] Meta-Analysis

Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19

COVID-19에 대한 회복기 혈장 요법의 인터페론-α2 자가항체

Original Article

Published on 2021-11-122022-09-10
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제,

[키워드] age Analysis association Auto-antibodies auto-antibody Concentration condition convalescent plasma convalescent plasma treatment COVID-19 COVID-19 patient COVID-19 patients Critically ill critically ill COVID-19 patients determine disease severity Donor Effect ELISA healthy controls Human plasma ICU patient ICU Patients IFN-α2 interferon Interferon alpha longitudinal Longitudinal analyses Neutralization assay neutralized Neutralizing not neutralize Patient performed physiological plasma positive proportion proportions respiratory Respiratory illness respiratory illnesses respiratory tract Result risk SARS-CoV-2 sera serum Sex supplementary material survival tested transfer Viral viral clearance Viral load virological outcome
[DOI] 10.1007/s10875-021-01168-3 PMC 바로가기 [Article Type] Original Article

Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment

회복기 혈장 치료를 받는 면역 저하된 숙주에서 여러 SARS-CoV-2 항체 탈출 변이체의 출현

Research Article

Published on 2021-08-252022-09-10
Journal: mSphere [Category] MERS, SARS, 변종, 진단,

[키워드] (Alpha) (Beta) accumulation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha anti-SARS-CoV-2 antibody B.1.1.7 B.1.351 B.1.617.2 Beta compromised immune status convalescent plasma Convalescent plasma therapy convalescent plasma treatment coronavirus COVID-19 pandemic Deletion deletions disease severity domain E484K Efficacy emergence escape Evidence evidence of Evolution FIVE genomic hosts hypothese hypotheses identify IgG immune escape mutants Immunocompromised Immunocompromised patient Immunocompromised patients Immunosuppressed Immunosuppression in vitro lentiviral Lineage lineages measure microevolution Multiple mutant mutants Mutation mutations N-terminal domain neutralization Neutralizing antibodies neutralizing antibody NTD observation over P.1 Patient Population Prolonged infection pseudovirus RBD RBD mutation RBD mutations RBD region Receptor-binding domain reduce reduced Region required respiratory S protein SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 genomes SARS-CoV-2 variant SARS-CoV-2 variants selective pressure sequence serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Spike protein steroid Steroids Support susceptibility Swab the S protein therapy total Ig tracheal tracheal aspirate Transmissibility Transmission unique Vaccine variants variants of concern Viral viral evolution VoC VOCs
[DOI] 10.1128/mSphere.00480-21 PMC 바로가기 [Article Type] Research Article

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Research

Published on 2021-06-172022-10-30
Journal: JAMA Oncology [Category] COVID-19,

[키워드] 30-Day mortality 95% CI 95% CIs administration Admission age all-cause mortality Analysis association benefit Cancer cancers Cohort cohort study collected conducted confounder confounding factors control patients convalescent plasma Convalescent plasma therapy convalescent plasma treatment COVID-19 Cox proportional hazard evaluate evaluated exposure finding hazard hematologic Hospitalization Hospitalized hospitalized patient HRs immunocompromised individual Importance individual intensive care Intervention knowledge life-threatening male measure mechanical ventilatory support Mortality objective outcome participant Patient patients plasma Point propensity score matching recipient regression analysis Relevance remained reported required Result retrospective cohort study risk factor secondary setting severe COVID-19 significantly significantly lower survival therapy Treatment was performed with COVID-19
[DOI] 10.1001/jamaoncol.2021.1799 PMC 바로가기 [Article Type] Research

Convalescent plasma treatment of critically ill intensive care COVID-19 patients

중환자 중환자실 COVID-19 환자의 회복기 혈장 치료

Clinical Trial

Published on 2021-05-012022-09-11
Journal: Transfusion [Category] MERS, SARS, 비임상, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus All the patient all the patients antibody antiviral drug antiviral drugs antiviral immune response applied average breath Clinical outcome Complication convalescent plasma treatment coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients Critically ill critically ill COVID-19 patients Deceased determined by died effective Efficacy eight enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Euroimmun FFP transfusion FIVE IgG IgG antibody immune responses Immunoglobulin Immunoglobulin G IMPROVE indicated Infectious disease infectious disease testing intensive care Intravenous immunoglobulin investigated life-threatening median multiple organ failure Neutralization assay Neutralizing titer neutralizing titers onset of symptoms organ Organ failure Patient patient survival patients plasma respiratory S1 protein SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody sera Seven severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 specific antibodies survivor the S1 protein treated Treatment
[DOI] 10.1111/trf.16392 PMC 바로가기 [Article Type] Clinical Trial

SARS-CoV-2 evolution during treatment of chronic infection

만성 감염 치료 중 SARS-CoV-2 진화

Case Reports

Published on 2021-04-012022-09-11
Journal: Nature [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody chronic infection compensating convalescent plasma Convalescent plasma therapy convalescent plasma treatment coronavirus Course Critical Deletion deletion mutant dominant Engagement Evidence evidence of Final Frequency Genotype human Ace2 protein Immunosuppressed in vitro individuals mutant Mutation N-terminal domain Neutralizing antibodies neutralizing antibody reduced Remdesivir respiratory S2 subunit SARS-CoV-2 SARS-CoV-2 evolution sensitivity sequence Sequencing serum antibodies serum antibody severe acute respiratory syndrome Coronavirus Spike protein Substitution susceptibility the spike protein These data transferred treated Treatment Viral viral evolution viral strain viral variant Viral variants virus virus infection viruses whole-genome wild-type wild-type SARS-CoV-2 wild-type virus
[DOI] 10.1038/s41586-021-03291-y PMC 바로가기 [Article Type] Case Reports

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis

COVID-19 환자의 회복기 혈장 치료와 임상 결과의 연관성: 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-03-232022-09-11
Journal: JAMA [Category] 임상,

[키워드] 95% CI all-cause mortality Analysis assessment assessment tool benefit Bia certainty Characteristics clinical Clinical deterioration Clinical improvement Clinical outcome clinical outcomes conducted convalescent plasma convalescent plasma treatment COVID-19 data extraction decrease development Evidence hazard ratio Hospital stay Inclusion inverse Limited mechanical ventilation Meta-analysis moderate Mortality no significant differences Other outcomes outcome outcomes Patient peer-reviewed Placebo plasma platform press primary analysis randomized clinical trial randomized clinical trials RCT RCTs Release releases review risk risk difference risk ratio searched selected Serious Adverse Event Serious Adverse Events significant differences significantly Standard of care synthesis Treatment treatment effects treatment for COVID-19 Trial
[DOI] 10.1001/jama.2021.2747 PMC 바로가기 [Article Type] Meta-Analysis

Successful pulsed methylprednisolone and convalescent plasma treatment in a case of a renal transplant recipient with COVID-19 positive pneumonia: a case report

Case Report

Published on 2021-03-162022-10-28
Journal: The Pan African Medical Journal [Category] COVID-19, MERS,

COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review

COVID-19: 분자 병태생리학, 유전적 진화 및 전향적 치료법—검토

Review

Published on 2021-02-082022-08-31
Journal: Archives of Microbiology [Category] 신약개발, 치료제,

[키워드] Chloroquine clinical trial contagious continuous monitoring convalescent plasma treatment COVID-19 COVID-19 pandemic Dexamethasone disease drug Drug discovery Drug repositioning/repurposing drug target effective Evolution Favipiravir form Genetic genomic globe had no Hydroxychloroquine life-threatening Lopinavir Lopinavir-ritonavir medical emergency molecular molecular evolution Molecular targets mortality rate no effect pandemic pathophysiology Patient Phylogenetic analysis recent recent finding recent findings recording reduce mortality reducing Remdesivir Ribavarin ribavirin Ritonavir severe forms of COVID-19 shown Side effects specific treatment Spread therapeutic therapeutic option Treatment Trial Viral
[DOI] 10.1007/s00203-021-02183-z PMC 바로가기 [Article Type] Review